Home
Science
MIRAM® Kit
Clinical Studies
News
Team
Careers
Contact
News
All news
Press Releases
May 7, 2024
Elypta Appoints Dr. Eva Pisa to Board of Directors
Apr 8, 2024
Elypta interim study results show glycosaminoglycan's potential to predict the risk of developing any-type cancer with a simple urine test
Jul 5, 2023
Elypta Receives ISO 13485:2016 Quality System Certification
Mar 28, 2023
The Roddenberry Foundation Awards Elypta $1 Million Grand Prize
Mar 15, 2023
Study in JCO Precision Oncology shows promising results supporting the use of glycosaminoglycan profiles (GAGomes) for monitoring and predicting response in patients with metastatic renal cell carcinoma
Dec 7, 2022
Double multi-cancer detection rate shown in the earliest stage using Elypta MIRAM® kit
Oct 20, 2022
Elypta recognized as one of Sweden's best start-ups
Aug 17, 2022
Elypta selected as one of the Winners of Falling Walls Venture 2022
Aug 10, 2022
Elypta appoints Volker Liebenberg as CMO
Jun 20, 2022
Elypta raises $21 million Series A to develop metabolism-based multi-cancer early detection test
Apr 4, 2022
Elypta launches Multi-Cancer Early Detection study to measure metabolic GAGome levels in adults at high risk of cancer in collaboration with the University of Leeds and Yorkshire Cancer Research
Feb 15, 2022
Elypta launches Multi-Cancer Early Detection screening study measuring metabolic GAGome levels in asymptomatic adults
Dec 15, 2021
Pivotal AUR87A study of GAGome-based liquid biopsy for kidney cancer recurrence opens 26th site
Dec 8, 2021
Elypta extends range of GAGome-based liquid biopsy applications
Jul 1, 2021
100th enrolled patient and more positive news
Jun 1, 2021
Elypta to present detection of any-stage cancer results at ASCO 2021
Feb 3, 2021
Elypta launches research service for glycosaminoglycan profiling
Jan 28, 2021
Elypta granted US patent for its liquid biopsy method based on cancer metabolism
Nov 27, 2020
AUR87A attracts interest at renowned urological congresses
Oct 14, 2020
AUR87A October 2020 update
Sep 15, 2020
Ethics approval completed in all countries
Sep 10, 2020
Elypta among Sweden's best 33 tech start-ups
Sep 9, 2020
Elypta HQ moves to Karolinska Institute campus
Feb 18, 2020
MilliporeSigma announced as contract manufacturer of Elypta's kits
Feb 18, 2020
Elypta among Nature Research and Merck's 44 spin-offs to watch
Feb 11, 2020
First patient enrolled in Elypta’s pioneering AUR87A renal cell carcinoma liquid biopsy trial
Jan 23, 2020
Elypta raises €6.1 million in a late seed round led by Industrifonden
Nov 15, 2019
Francesco Gatto wins SKAPA-priset
Sep 11, 2019
Elypta wins Nordic Life Science Award 2019
Sep 6, 2019
Elypta announces initiation of the pivotal AURORAX-087A study
Aug 16, 2019
Elypta nominated for Best Technological Innovation in Diagnostics by Medtech Insight
Jul 23, 2019
Elypta met with the FDA regarding AUR87A
Jul 2, 2019
Elypta named Nordic start-up of the year in the Serendipity Challenge
Jun 17, 2019
Elypta in final top 50 of the Serendipity Challenge
May 15, 2019
Elypta visited by Dr Robert Langer
May 7, 2019
Genetic Engineering News places Francesco Gatto among top 10 rising stars under 40
May 6, 2019
AURORAX project co-funded by the European Union started on May 1st
Apr 10, 2019
Elypta participated in the Swedish American Life Science Summit in Washington DC
Mar 27, 2019
Elypta interviewed on BBC podcast - The Naked Scientist
Mar 8, 2019
Elypta selected to present at BIO Europe Spring Start-up spotlight
Feb 27, 2019
In-depth article on Elypta in 360Dx
Feb 4, 2019
Elypta awarded €2.35 million from Horizon 2020 SME instrument
Dec 10, 2018
Francesco Gatto recognized as the top pioneer among Innovators under 35 in Europe
Nov 6, 2018
Francesco Gatto recognized among Europe's top 35 Innovators Under 35
Oct 24, 2018
Elypta again named among world's top 500 DeepTech start-ups
Oct 12, 2018
Elypta receives EIT Health Digital Sandbox grant
Jun 22, 2018
Francesco Gatto interviewed by Labiotech.eu
Feb 20, 2018
Anders Ekblom joins Elypta's board of directors
Jul 14, 2017
Elypta among Top 500 Deep-Tech Startups
